▼ 0.21%
prev close
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
Congressional Trades
1
All tracked trades
Members Trading
1
Unique members
Net Activity
-1
0 buys · 1 sells
Members Who Traded This Stock
1 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2023-04-10 | FOLDAmicus Therapeutics, Inc. | Sell | $1,001 - $15,000 | 1049d ago | — |
2023-04-10
Daniel Goldman
FOLD
Amount
$1,001 - $15,000
Filed
1049d ago
Recent News
Powered by Polygon.io
Halper Sadeh LLC is Investigating Whether RAPT, CTGO, TBN, FOLD are Obtaining Fair Deals for their Shareholders
$HAREHOLDER ALERT: The M&A Class Action Firm Encourages $hareholders to Act Before the Vote—RAPT, FOLD, TBN, and CTGO
Halper Sadeh LLC Encourages EKSO, FOLD, CWAN, JHG Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC Encourages EKSO, FOLD, CWAN, JHG Shareholders to Contact the Firm to Discuss Their Rights
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Clearwater Analytics Holdings, Inc. (NYSE - CWAN), Katapult Holdings, Inc. (Nasdaq - KPLT), Janus Henderson Group plc (NYSE - JHG), Amicus Therapeutics, Inc. (Nasdaq - FOLD)
Trade Timeline
Congressional activity, newest first
Daniel Goldman
2023-04-10 · Sale
$1,001 - $15,000